Format

Send to

Choose Destination
Blood. 2014 Nov 20;124(22):3191-6. doi: 10.1182/blood-2014-06-583617. Epub 2014 Oct 8.

Biosimilars: the science of extrapolation.

Author information

1
Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany;
2
Finnish Medicines Agency, Helsinki, Finland;
3
Paul-Ehrlich-Institut, Langen, Germany;
4
Medicines and Healthcare Products Regulatory Agency, London, United Kingdom;
5
Danish Health and Medicines Authority, Copenhagen, Denmark; and Twincore Centre for Experimental and Clinical Infection Research, Hannover, Germany.

Abstract

Despite the establishment of a specific approval pathway, the issuance of detailed scientific guidelines for the development of similar biological medicinal products (so-called "biosimilars") and the approval of several biosimilars in the European Union, acceptance of biosimilars in the medical community continues to be low. This is especially true in therapeutic indications for which no specific clinical trials with the biosimilar have been performed and that have been licensed based on extrapolation of efficacy and safety data from other indications. This article addresses the concerns frequently raised in the medical community about the use of biosimilars in such extrapolated indications and explains the underlying scientific and regulatory decision making including some real-life examples from recently licensed biosimilars.

PMID:
25298038
DOI:
10.1182/blood-2014-06-583617
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center